Dr. Shaughnessy on the Emergence of CAR T-Cell Therapy in Hematologic Malignancies

Video

Paul J. Shaughnessy, MD, discusses the emergence of CAR T-cell therapy in hematologic malignancies.

Paul J. Shaughnessy, MD, hematologist, oncologist, and medical director of Adult Blood and Marrow Transplant Program at the Methodist Hospital, discusses the emergence of CAR T-cell therapy in hematologic malignancies.

CAR T-cell therapy ​has demonstrated encouraging activity in adults with relapsed/refractory non-Hodgkin lymphoma and pediatric patients with relapsed/refractory acute lymphoblastic leukemia, says Shaughnessy

​Several ongoing studies are​ evaluating CAR T-cell therapy ​in multiple myeloma and other ​types of lymphoma, explains Shaughnessy. Moreover, the encouraging results observed thus far ​suggest that CAR T-cell therapy will receive regulatory approval in additional indications in the future.

Beyond the hematologic space, CAR T-cell therapy could ​have utility in solid tumors, Shaughnessy concludes.

Related Videos
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
Alan Beggs, PhD, on Challenges in Therapeutic Development for Rare Diseases
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
PJ Brooks, PhD
John DiPersio, MD, PhD, the director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine
© 2024 MJH Life Sciences

All rights reserved.